Daymark Wealth Partners LLC Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Daymark Wealth Partners LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 55.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,851 shares of the company’s stock after selling 3,551 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $245,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of NVO. Albion Financial Group UT lifted its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the period. Nisa Investment Advisors LLC raised its position in Novo Nordisk A/S by 36.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company’s stock worth $129,000 after acquiring an additional 400 shares during the period. Genesis Private Wealth LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $252,000. Beaumont Financial Advisors LLC increased its stake in Novo Nordisk A/S by 3.6% during the 4th quarter. Beaumont Financial Advisors LLC now owns 16,616 shares of the company’s stock worth $1,429,000 after buying an additional 572 shares in the last quarter. Finally, Atomi Financial Group Inc. raised its stake in Novo Nordisk A/S by 4.8% in the 4th quarter. Atomi Financial Group Inc. now owns 32,146 shares of the company’s stock valued at $2,765,000 after purchasing an additional 1,473 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NVO stock opened at $87.94 on Friday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The firm has a market cap of $394.65 billion, a PE ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a 50-day moving average of $95.62 and a two-hundred day moving average of $115.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.